# Siltuximab to Decrease Symptom Burden After Autologous Stem Cell Transplantation for Patients With Multiple Myeloma and AL Amyloidosis

Source: https://onco.cc/trials/nct03315026/  
OnCo record `nct03315026` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Siltuximab in Multiple myeloma, run by Memorial Sloan Kettering Cancer Center, active and no longer recruiting.

## Summary

Siltuximab to Decrease Symptom Burden After Autologous Stem Cell Transplantation for Patients With Multiple Myeloma and AL Amyloidosis is a phase 2 interventional study registered as NCT03315026 by Memorial Sloan Kettering Cancer Center, with 30 participants planned, started 2017-12-14 and due to reach its primary completion in 2026-10. Interventions recorded: Siltuximab, The M.D. Anderson Symptom Inventory (MDASI). Conditions recorded: Multiple Myeloma, AL Amyloidosis.

Linked to the drug Siltuximab because the registry names it among its interventions and Multiple myeloma among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT03315026
- Phase: 2
- Setting: Phase II Study of Interleukin 6 Blockade With Siltuximab to Decrease Symptom Burden in Patients Age 60-75 Undergoing Autologous Stem Cell Transplantation for Multiple Myeloma and AL Amyloidosis
- Sponsor: Memorial Sloan Kettering Cancer Center
- Enrolled: 30

## Sources

- ClinicalTrials.gov NCT03315026: https://clinicaltrials.gov/study/NCT03315026

## Connected records

- cancers: [Multiple myeloma](https://onco.cc/cancers/multiple-myeloma/)
- drugs: [Siltuximab](https://onco.cc/drugs/siltuximab/)

---
JSON: https://onco.cc/api/v1/entities/nct03315026.json